Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and in Vivo Evidence

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-12-1708
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Low Serum miR-19a Expression as a Novel Poor Prognostic Indicator in Multiple Myeloma

International Journal of Cancer
Cancer ResearchOncology
2014English

Curcumin as a Therapeutic Agent: The Evidence From in Vitro, Animal and Human Studies

British Journal of Nutrition
MedicineNutritionDietetics
2010English

A Novel Selective Small-Molecule PI3K Inhibitor Is Effective Against Human Multiple Myeloma in Vitro and in Vivo

Blood Cancer Journal
OncologyHematology
2013English

STK405759 as a Combination Therapy With Bortezomib or Dexamethasone, in in Vitro and in Vivo Multiple Myeloma Models

Oncotarget
Oncology
2018English

Proteasome Inhibitors Block Myeloma-Induced Osteocyte Death in Vitro and in Vivo in Multiple Myeloma Patients

Blood
BiochemistryImmunologyCell BiologyHematology
2012English

EZH2 as a Therapeutic Target for Multiple Myeloma and Other Haematological Malignancies

Biomarker Research
BiochemistryMolecular MedicineClinical Biochemistry
2018English

MicroRNA-34a (miR-34a)

Science-Business eXchange
2011English

A Novel Alkylating Agent Melflufen Induces Irreversible DNA Damage and Cytotoxicity in Multiple Myeloma Cells

British Journal of Haematology
Hematology
2016English

The Tumor-Suppressive and Potential Therapeutic Functions of miR-34a in Epithelial Carcinomas

Expert Opinion on Therapeutic Targets
Molecular MedicineDrug DiscoveryClinical BiochemistryPharmacology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy